The U.S. District Court for the Eastern District of Pennsylvania denied Johnson & Johnson’s motion to dismiss Pfizer’s antitrust litigation, which alleges that J&J engaged in anticompetitive practices for its biologic Remicade (infliximab) to block biosimilars.
Source: Drug Industry Daily